AKBA
Akebia Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 2 ▼ 6 insiders sell $900.8K at $1.39
- Feb 26 ▲ Akebia Therapeutics reported strong financial results for Q4 and ful…
- Mar 4 ▲ 1 insider buy $86.6K at $1.25
- Jun 29 ▼ 1 insider sell $62.2K at $1.11
- Jun 30 ▲ Akebia Therapeutics and U.S. Renal Care announced that the VOICE tri…
- Sep 4 Trial readout: Results Pending: Erythropoiesis-Stimulating Agent (ESA) (P…
- Sep 8 WestPark Capital initiates
- Sep 8 Trial readout: Results Pending: Erythropoiesis-Stimulating Agent (ESA) (P…
- Oct 12 Trial readout: Results Pending: Erythropoiesis-Stimulating Agent (ESA) (P…
- Oct 23 ▼ Akebia Therapeutics received a Nasdaq deficiency notice on October 2…
- Oct 26 ▲ Akebia Therapeutics announced positive VOICE trial data for Vafseo (…
- Oct 26 FDA: U.S. Renal Care Presents Analysis of VOICE Trial Demonstra…
- Nov 16 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $86.6K at an average $1.25. 6 insiders sold $963.0K. Price is 64% below their cost.
- InstitutionsBEARISH
Q3 2026: 13 added (0 new), 26 trimmed or exited.
- AnalystsBULLISH
10 of 12 rate it Buy or better. Every target is above the price.
- Short sellersBUILDING
Short interest +17.9% to 27.20M shares. 3.0 days to cover, ≈9.8% of shares.
- TrendDOWNTREND
41% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 5.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $3.3M |
| RENAISSANCE TECHNOLOGIES LLC | ADD | $1.7M |
| Qube Research & Technologies Ltd | TRIM | $722.3K |
| ALPS ADVISORS INC | ADD | $335.0K |
| MORGAN STANLEY | TRIM | $282.3K |
| IEQ CAPITAL, LLC | ADD | $135.8K |
| Creative Planning | NEAR_EXIT | $124.7K |
| JPMORGAN CHASE & CO | TRIM | $121.0K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
12 analystsPrice is below the lowest target. Median implies +568%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Nov 6, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Nov 5, 2026 | BTIG MAINTAIN | Buy |
| Sep 15, 2026 | BTIG REITERATE | Buy |
| Sep 8, 2026 | WestPark Capital INITIATE | Buy |
| Aug 7, 2026 | Leerink Partners DOWNGRADE | Market Perform |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Butler John P. CEO and President Aug 6, 2026 | EXERCISE | $220.5K |
Ostrowski Erik SVP, CFO, CBO & Treasurer Jun 29, 2026 | SELL | $62.2K |
ADAMS ADRIAN Director Jun 17, 2026 | AWARD | 53,600 sh |
ZUMWALT LEANNE M Director Jun 17, 2026 | AWARD | 35,700 sh |
ADAMS ADRIAN Director Jun 17, 2026 | AWARD | 35,700 sh |
ZUMWALT LEANNE M Director Jun 17, 2026 | AWARD | 53,600 sh |
FRIESON RON Director Jun 17, 2026 | AWARD | 35,700 sh |
FRIESON RON Director Jun 17, 2026 | AWARD | 53,600 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
9 filings · 2 press releases · 2 bullish · 3 bearish · 1 mixed · 3 neutral- NEUTRAL 8-KNov 16, 2026
Akebia Therapeutics entered into a $140M senior secured term loan facility with Symbiotic Capital, receiving an initial $60M tranche used to repay its existing $55M BlackRock/Kreos loan. The company also issued warrants for 3,441,352 shares at $0.6974 per share.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL PRESS RELEASENov 16, 2026
Akebia Therapeutics entered into a $60M senior secured term loan facility with Symbiotic Capital, using the proceeds to fully repay a $55M BlackRock loan. An additional $80M discretionary tranche is available.
🔒 Fresh report (last 24h), subscribers only
- BEARISH 8-KNov 5, 2026
Akebia reported Q3 2026 total revenue of $36.9M, down 37% YoY from $58.8M, driven by a 53% decline…
The sharp decline in Auryxia revenue from generic erosion is now the dominant headwind, and Vafseo revenue is not yet growing fast enough to offset it. Watch for the TDAPA expiration impact on…
- BEARISH PRESS-RELEASENov 5, 2026
Akebia reported Q3 2026 total revenue of $36.9M, down 37% YoY from $58.8M, driven by a 53% decline…
The core issue is Auryxia's accelerating decline from generic erosion, which is not offset by Vafseo's patient growth due to inventory destocking and TDAPA uncertainty. Monitor Q4 for Vafseo revenue…
All AKBA filing & press-release reports (11)
- 8-K reportNov 16, 2026
- PRESS-RELEASE reportNov 16, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- PRESS-RELEASE reportOct 26, 2026
- 8-K reportOct 23, 2026
- 8-K reportOct 14, 2026
- INST-CLUSTER reportSep 22, 2026
- 8-K reportJun 30, 2026
- PRESS-RELEASE reportApr 30, 2026
- 8-K reportFeb 26, 2026